In addition, we observed that the inhibitor CA3 (IL56) effectively nullified the influence of CMD‐BHQ3‐PTL/DOX@RBCm on SOX9 expression, suggesting that the reduction in SOX9 expression by CMD‐BHQ3‐PTL/DOX@RBCm was achieved by inhibiting the Hippo/YAP1/TAZ signaling pathway in CRC (Figure 7H,J). The gene discussed is SOX9; the disease is colorectal carcinoma.